Oral & Salivary Cancer Biology Program

The Oral and Salivary Cancer Biology Program supports basic and translational research to improve detection and treatment of cancers of the Oral Cavity, Pharynx, and Salivary Glands. Basic research focuses on susceptibilities and mechanisms that influence tumor initiation, promotion, and progression. Translational research focuses on development of innovative biomarkers, novel diagnostic technologies, and appropriate human specimens to better characterize cancers and improve medical decision making and treatment response evaluation.

Staff Contacts

Funding Opportunity Announcements

Title Staff Contact Opportunity Number Activity Code Expiration Date
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) PAR-18-530 R01
Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed) PA-17-460 R21
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for years 2018, 2019 and 2020 (P50) PAR-18-313 P50
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) PA-18-484 R01
Biology of Lung, and Head and Neck Preneoplasias (R01- Clinical Trial Not Allowed) PA-17-459 R01
Change of Grantee Organization (Type 7 Parent) PA-18-590 C06, D43, D71
Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-18-591 C06, D43, D71
Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) RFA-RM-21-007 R03
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional) PA-18-738 R01
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional) PA-18-739 R21
Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Not Allowed) PAR-18-714 R15
Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed) PA-18-837 R41, R42, R43
Precision Imaging of Oral Lesions (R21-Clinical Trial Not Allowed) PAR-18-788 D71, R21
Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed) PAR-18-787 R01
The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional) RFA-OD-19-029 R01
NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) PA-19-091 R01
NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) PA-19-092 R21
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) PAR-19-134 R15
NIH Administrative Supplements to Recover Losses Due to Hurricanes Harvey, Irma, and Maria Under the Bipartisan Budget Act of 2018 Non-Construction (Admin Supp Clinical Trial Optional) PA-18-936 D43, D71, DP1
Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) PA-18-935 K01, K08, K23
Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed) PAR-19-172 R01
Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed) PAR-19-173 R21
Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) PAR-19-194 R21
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) PAR-20-277 R21
Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01 Clinical Trial Not Allowed) PAR-19-292 R01
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) PAR-20-155 R01
Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed) PAR-19-293 R21
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) PAR-20-276 R01
NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed) PAR-19-370 R03
Development of Highly Innovative Tools and Technology for Analysis of Single Cells (STTR) (R41/R42 Clinical Trial Not Allowed) PA-20-025 R41, R42
Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed) PA-20-047 R43, R44
NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed) PAR-20-060 U01
Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional) PA-20-135  C06, D43, D71
Administrative Supplements for Research on Dietary Supplements (Admin Supp-Clinical Trial Not Allowed) PA-20-227 D43, D71, DP1
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) PA-20-185 R01
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) PA-20-207 R13
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) PA-20-195 R21
Successor-in-Interest (Type 6 Parent Clinical Trial Optional) PA-20-275 C06, D43, D71
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-20-272 C06, D43, D71
Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional) PAR-20-179 R01
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) PAR-21-038 R01
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required) PAR-21-039 R01
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, 2023 (P50 Clinical Trial Required) PAR-20-305 P50